<DOC>
	<DOCNO>NCT00439959</DOCNO>
	<brief_summary>This study represent first administration GSK625433 human . The study design evaluate initial safety tolerability healthy adult well anti-viral activity Hepatitis C ( HVC ) infect adult . The way human body process GSK625433 also investigate .</brief_summary>
	<brief_title>Monotherapy Versus Placebo Over 14 17 Days Healthy Hepatitis C Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Inclusion criterion : Healthy male &amp; female Part 1 age 1860 Part 2 age 1850 &amp; 6580 Within normal weight range give height Negative urine drug alcohol test Willing follow study procedure Exclusion criterion : Any significant abnormal lab , ECG , medical physical exam find screen Allergy study drug Excessive alcohol intake Positive HIV hepatitis B C result Use prescription nonprescription drug within one week study start except birth control Blood pressure med &amp; Tylenol Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>GSK625433 ,</keyword>
	<keyword>Hepatitis C ,</keyword>
	<keyword>metabolic probe ,</keyword>
	<keyword>food-effect ,</keyword>
	<keyword>HCV ,</keyword>
	<keyword>FTIH</keyword>
	<keyword>polymerase ,</keyword>
</DOC>